NEW YORK, March 15, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600:
Following is a summary of the changes that will take place prior to the open of trading on the effective date:
Effective Date | Index Name | Action | Company Name | Ticker | GICS Sector | |
March 21, 2023 | S&P SmallCap 600 | Addition | CVR Energy | CVI | Energy | |
S&P SmallCap 600 | Deletion | Atlas Air Worldwide Holdings | AAWW | Industrials | ||
March 22, 2023 | S&P MidCap 400 | Addition | Exponent | EXPO | Industrials | |
S&P MidCap 400 | Deletion | IAA | IAA | Industrials | ||
S&P SmallCap 600 | Addition | Certara | CERT | Health Care | ||
S&P SmallCap 600 | Deletion | Exponent | EXPO | Industrials | ||
For more information about S&P Dow Jones Indices, please visit www.spdji.com
ABOUT S&P DOW JONES INDICES
S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.
S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.
FOR MORE INFORMATION:
S&P Dow Jones Indices
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Inquiries
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$11.88 |
Daily Change: | 0.26 2.24 |
Daily Volume: | 1,504,465 |
Market Cap: | US$1.910B |
May 05, 2025 April 14, 2025 April 14, 2025 April 01, 2025 February 26, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load